Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia  by Bicocca, Vincent T. et al.
Cancer Cell
ArticleCrosstalk between ROR1
and the Pre-B Cell Receptor Promotes Survival
of t(1;19) Acute Lymphoblastic Leukemia
Vincent T. Bicocca,1,5 Bill H. Chang,2,5 Behzad Kharabi Masouleh,6 Markus Muschen,6,7 Marc M. Loriaux,3,5
Brian J. Druker,1,5,8 and Jeffrey W. Tyner4,5,*
1Division of Hematology and Medical Oncology
2Division of Pediatric Hematology and Oncology, Department of Pediatrics
3Department of Pathology
4Department of Cell and Developmental Biology
Oregon Health & Science University, Portland, OR 97239, USA
5Knight Cancer Institute, Portland, OR 97239, USA
6Childrens Hospital Los Angeles and Leukemia and Lymphoma Program, Norris Comprehensive Cancer Center, University of Southern
California, Los Angeles, CA 90027, USA
7Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA
8Howard Hughes Medical Institute, Portland, OR 97239, USA
*Correspondence: tynerj@ohsu.edu
http://dx.doi.org/10.1016/j.ccr.2012.08.027SUMMARYWe report that t(1;19) ALL cells universally exhibit expression of and dependence on the cell surface receptor
ROR1.We further identify t(1;19) ALL cell sensitivity to the kinase inhibitor dasatinib due to its inhibition of the
pre-B cell receptor (pre-BCR) signaling complex. These phenotypes are a consequence of developmental
arrest at an intermediate/late stage of B-lineage maturation. Additionally, inhibition of pre-BCR signaling
induces further ROR1 upregulation, and we identify distinct ROR1 and pre-BCR downstream signaling path-
ways that are modulated in a counterbalancing manner—both leading to AKT phosphorylation. Consistent
with this, AKT phosphorylation is transiently eliminated after dasatinib treatment, but is partially restored
following dasatinib potentiation of ROR1 expression. Consequently, ROR1 silencing accentuates dasatinib
killing of t(1;19) ALL cells.INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common form
of childhood malignancy, accounting for 25% of all childhood
cancers. Although great strides have been made in the treat-
ment of childhood leukemia, close to 20% of patients will
have resistant disease eventually leading to death. To improve
outcomes for these patients, it is critical to develop new thera-
peutic strategies that specifically target the cellular processes
causing malignancy. This necessitates a comprehensive knowl-
edge of the gene targets driving oncogenesis in each patient.Significance
The 1;19 translocation is one of the most common recurring c
(ALL). We have identified a therapeutic gene target, ROR1, for
tinib, with universal efficacy against t(1;19) ALL cells due to inh
equisite pathway for t(1;19) ALL. These phenotypes are reca
stage, such as t(17;19) ALL, as well as mature B cell maligna
signaling pathways downstream of ROR1, which cooperate
link between the pre-BCR and ROR1 and the importance of in
656 Cancer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier IncFrom both a biological and clinical standpoint, tyrosine kinases
represent an important gene family for interrogation because
tyrosine kinases have been implicated in the genesis of
a wide variety of malignancies, including certain subsets of
ALL, and tyrosine kinase inhibitors are already in clinical use
with remarkable outcomes (Krause and Van Etten, 2005). Unfor-
tunately, most patients with ALL still present without knowledge
of the specific tyrosine kinases that are operationally important
in disease pathogenesis. As such, we have performed func-
tional profiling to identify tyrosine kinase targets in patients
with ALL.hromosomal abnormalities in acute lymphoblastic leukemia
t(1;19) ALL. We have also identified a kinase inhibitor, dasa-
ibition of the pre-B cell receptor (pre-BCR)—another oncor-
pitulated in other ALL cells of intermediate developmental
ncies, such as t(8;14) Burkitt’s. Finally, we have identified
with pre-BCR signaling. Our findings highlight a functional
hibiting both pathways to augment tumor cell killing.
.
Figure 1. ROR1 Is a Functional Target in t(1;19) ALL
White blood cells (2.253 107) from a t(1;19)-positive patient with ALL (07-112)
were suspended in siPORT buffer and incubated with 1 mM siRNA from an
siRNA library individually targeting each member of the tyrosine kinase family
as well as N-RAS, K-RAS, and single and pooled nonspecific siRNA controls.
Cells were electroporated on a 96-well electroporation plate at 1110 V
(equivalent of 150 V), 200 ms, and 2 pulses. Cells were replated into culture
media, and cell viability was determined by addition of a tetrazolium salt (MTS
assay) at day 4 after electroporation. Values represent percentage mean
(normalized to the median value on the plate) ± SEM (n = 3).
See also Figure S1.
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ROR1 and Dasatinib in t(1;19)-ALLOne of the most common, recurring translocations found in
patients with ALL is t(1;19)(q23;p13), which is observed in
approximately 5% of all pediatric ALL cases as well as 1%–
2% of adult ALL cases. Greater than 90% of patients with
t(1;19) exhibit blasts with expression of cytoplasmic immuno-
globulin heavy-chain m (Igm) and an absence of CD34 on the
cell surface, indicating that t(1;19) blasts are typically arrested
at a later stage of B cell differentiation (large/small pre-BII)
compared with most other ALL subsets (Hunger, 1996; Williams
et al., 1984). The 1;19 translocation results in the fusion tran-
scription factor complex E2A-PBX1 (Hunger et al., 1991; Kamps
et al., 1991), which has been shown to induce myeloid, T-
lymphoid, and B-lymphoid malignancies in mouse models (Bijl
et al., 2005; Dedera et al., 1993; Kamps and Baltimore, 1993;
Kamps et al., 1991).
RESULTS
ROR1 Is a Therapeutic Gene Target in t(1;19) ALL
To identify tyrosine kinase gene targets in patients with ALL, we
tested clinical specimens from pediatric patients with ALL by
gene-silencing with an siRNA library that collectively targets
the tyrosine kinome. Cells were electroporated with prevalidated
siRNAs that individually target each tyrosine kinase, as well as
nonspecific control siRNA (Tyner et al., 2008, 2009). After
4 days in culture, cells were subjected to an MTS assay for
assessment of cell viability. Evaluation of the t(1;19)-positive
sample 07-112 revealed hypersensitivity to siRNA targeting the
receptor tyrosine kinase ROR1 (Figure 1; see Figure S1A avail-
able online). Other ALL cases with normal karyotype (sample
08-026 is used as an example), did not exhibit sensitivity to
ROR1 silencing (Figure S1B). Further evaluation by RT-PCR
revealed overexpression of ROR1 in sample 07-112 at levels
comparable to artificial ROR1 overexpression in Ba/F3 cells,
whereas sample 08-026 did not exhibit detectable ROR1
expression (Figure S1C).CanROR1 Expression and Functional Dependence Is
Universal in t(1;19) ALL
To test whether the ectopic expression of ROR1 observed in
t(1;19) patient 07-112 was uniformly detectable in all t(1;19)
ALL samples, we obtained ten pediatric ALL samples (gener-
ously provided by the Children’s Oncology Group ALL Biology
Laboratory) and two cell lines that are positive for t(1;19)
and compared them with five pediatric ALL samples and
two cell lines that are t(1;19) negative. We observed that
all t(1;19)-positive samples exhibited ROR1 overexpression,
whereas none of the t(1;19)-negative samples or normal white
blood cells displayed the same phenotype (Figure 2A; Fig-
ure S2A). Overexpression of ROR1 protein was also observed
by immunoblot and FACS analysis on t(1;19)-positive cells
(Figures 2B and 2C).
To assess the extent and exclusivity of ROR1 expression in
a larger cohort of patient samples, we examined microarray
meta-analysis data generated from pediatric patients with ALL
and normal B cell progenitors (Trageser et al., 2009). We
compared t(1;19) patients with ALL with those carrying
t(9;22) (BCR-ABL), t(12;21) (ETV6-RUNX1), or patients with
MLL (11q23) gene rearrangements. In addition, we evaluated
ROR1 levels in distinct, normal B-lineage progenitor populations
(CD34+ Lin, pro-B, pre-BI, pre-BII large, pre-BII small, and
immature B cells). We observed higher levels of ROR1 expres-
sion on every t(1;19) patient compared with all patients from
each of the other leukemic subsets. Similarly, t(1;19) patients
showed higher levels of ROR1 expression comparedwith normal
B cell progenitor populations at the earliest stages of B-lineage
development (CD34+ Lin, pro-B, and pre-BI). However, when
compared with normal B-lineage cells at an intermediate stage
of B cell development (large/small pre-BII and immature B), we
observed high levels of ROR1, similar to those seen on t(1;19)
cells (Figure 2D). These results support recent findings showing
ROR1 cell surface expression on intermediate stages of normal
B cell development (Broome et al., 2011; Hudecek et al.,
2010). Importantly, these and other studies did not observe
ROR1 expression on normal, mature B cells or plasma cells
(Baskar et al., 2008; Fukuda et al., 2008; Hudecek et al., 2010).
Hence, in nonmalignant B-lineage cells, ROR1 expression
appears to be absent at the earliest stages of development,
becomes highly expressed at intermediate/late stages, and is
then downregulated in normal, mature B cells. Interestingly,
the vast majority of blasts from t(1;19) patients are arrested at
this intermediate/late stage of B-lineage development (large/
small pre-BII). Hence, these data suggest that high ROR1
expression in t(1;19) may be a product of the comparatively
mature differentiation state of these malignant blasts and may
not be due to aberrant transcription profiles of the chimeric
transcription factor E2A-PBX1. Subsequent examination of the
E2A-PBX1 transcription factor in t(1;19) cell lines supports
this hypothesis, because siRNA-mediated knockdown of E2A-
PBX1 in the t(1;19) cell line RCH-ACV showed a corresponding
knockdown of the E2A-PBX1 transcriptional target WNT16B
(McWhirter et al., 1999), but had no effect on expression of
ROR1 (Figure S2B).
Because the two t(1;19) cell lines, RCH-ACV and Kasumi-2,
recapitulated the ROR1 expression profile observed in t(1;19)-
positive primary specimens, we next tested whether these cellcer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier Inc. 657
Figure 2. ROR1 Is Universally Expressed
and a Therapeutic Target in t(1;19) ALL
(A) cDNA derived from t(1;19)-positive and -nega-
tive cell lines and primary patient samples was
amplified using primers specific for ROR1, E2A-
PBX1, or GAPDH, and PCR products were
analyzed by gel electrophoresis.
(B) Whole-cell extracts derived from t(1;19)-posi-
tive and -negative cell lines and primary patient
samples were subjected to immunoblot analysis
using antibodies specific for ROR1, E2A-PBX1, or
b-Actin.
(C) Flow cytometric analysis of t(1;19)-positive
and -negative cell lines was performed using
specific polyclonal antihuman ROR1 antibodies
(dark gray histogram) versus isotype control (light
gray histogram).
(D) Gene expression microarray data for pediatric
patients with ALL and normal B cell progenitor
populations were compiled into a meta-analysis.
Patients with MLL gene rearrangements t(9;22)
(BCR-ABL), t(12;21) (TEL-AML), or t(1;19) (E2A-
PBX1) (n = 15 for each subset) and nonmalignant
B cell progenitor populations (CD34+ Lin, pro-B,
pre-B, pre-BII large, pre-BII small, and immature
B) (n = 15 total) were examined, and Affymetrix
intensity values for ROR1 are plotted for each
individual patient sample (**p < 0.01).
(E) RCH-ACV or Kasumi-2 cells (both t(1;19)-
positive) as well as REH cells (t(12;21)-positive)
were electroporated in the presence of nonspe-
cific or ROR1-targeting siRNA and plated into
culture media. After 3 days, a sample of cells was
harvested for immunoblot analysis using anti-
bodies specific for ROR1 or b-Actin. After 4 days,
cells were subjected to an MTS assay to measure
cell viability. Values represent percentage mean
(normalized to nonspecific control wells) ± SEM
(n = 10) (**p < 0.01).
(F) RCH-ACV cells stably expressing ROR1-V5 or
LacZ control were electroporated in the presence
of nonspecific or ROR1 UTR-targeting siRNA
and plated into culture media. After 3 days, a
sample of cells was harvested for immunoblot
analysis using antibodies specific for ROR1, V5, or
b-Actin. After 4 days, cells were subjected to an
MTS assay to measure cell viability. Values represent percentage mean (normalized to nonspecific control wells) ± SEM (n = 6) (**p < 0.01).
(G) Primary cells from a t(1;19) patient with ALL were propagated in NOD-SCID mice lacking the IL-2 receptor g chain. Xenograft cells were harvested from bone
marrow and spleen of overtly leukemic mice and electroporated with nonspecific or ROR1-targeting siRNA. After 4 days, cells were subjected to an MTS assay
to measure cell viability. Values represent percentage mean (normalized to nonspecific control wells) ± SEM (n = 4) (*p < 0.05).
(H) Primary cells from a t(1;19) patient with ALL were propagated in a xenograft mouse model as above, and RNA was harvested from cell extracts. PCR was
performed on cDNA with primers specific for ROR1, E2A-PBX1, or GAPDH. The t(1;19) positive (RCH-ACV) and negative (REH) cell lines were included for
comparison.
See also Figure S2.
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ROR1 and Dasatinib in t(1;19)-ALLlines were also sensitive to ROR1 silencing, as we observed with
sample 07-112. We treated both cell lines as well as the control
t(1;19)-negative cell line REH with siRNA specific for ROR1.
Consistent with the results from sample 07-112, both RCH-
ACV and Kasumi-2 cells were sensitive to ROR1 silencing (Fig-
ure 2E). Loss of ROR1 resulted in reduced cell growth and
increased apoptosis (Figure S2C). In addition, treatment of
RCH-ACV cells with three individual siRNA duplexes that target
different portions of the ROR1 open reading frame (ORF), as well
as three individual siRNA duplexes that target different portions
of the ROR1 30-untranslated region (UTR), resulted in reductions658 Cancer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier Incof RCH-ACV cell viability that were always proportional to the
respective silencing capacity of each siRNA duplex (Figures
S2D and S2E). Similarly, stable overexpression of an ORF-only
ROR1 construct in RCH-ACV cells rescued cell viability when
treated with an siRNA duplex targeting the ROR1 30-UTR (Fig-
ure 2F), confirming that the siRNA-mediated killing of t(1;19) cells
is due to a ROR1-specific phenomenon. We next confirmed that
this finding was reproducible in early passage t(1;19) cells prop-
agated by xenograft into NOD/SCID mice. Xenograft cells
derived from four t(1;19) patients were tested for ROR1 overex-
pression as well as for sensitivity to ROR1 siRNA. We found that.
Figure 3. Pre-BCR Signaling Inhibition
Impairs t(1;19) Cell Viability and Activates
ROR1 Expression
(A) RCH-ACV cells were electroporated in the
presence of nonspecific siRNA or siRNA targeting
Iga, Igb, or both and then plated in culture media.
After 3 days, a sample of cells was harvested for
immunoblot analysis using antibodies specific for
Iga, Igb, or b-Actin. After 4 days, cells were sub-
jected to an MTS assay to measure cell viability.
Values represent percentage mean (normalized to
nonspecific control wells) ± SEM (n = 6) (**p < .01).
(B) RCH-ACV cells were electroporated in the
presence of nonspecific or Iga and Igb-targeting
siRNA and then were plated in culture media. After
3 days, cells were harvested for immunoblot
analysis using antibodies specific for ROR1,
Iga, Igb, or b-Actin. One representative blot is
included. Densitometry was performed to quanti-
tate ROR1 expression. Values represent per-
centage mean (normalized to nonspecific
control) ± SEM (n = 3) (**p < .01).
(C) RCH-ACV, Kasumi-2, and REH cells were
cultured in graded concentrations of the kinase
inhibitor dasatinib for 3 days, at which time
cells were subjected to an MTS assay for
measurement of cell viability. Values represent
percentage mean (normalized to no-drug control
wells) ± SEM (n = 6).
(D) RCH-ACV cells were cultured in graded
concentrations of dasatinib for 96 hr before being
stained with Annexin-V PE and 7-AAD and were
analyzed by flow cytometry to determine induction
of apoptosis. Values represent the percentage
of total positive cells ± SEM (n = 3) (*p < .05;
**p < .01).
(E and F) RCH-ACV cells were cultured in the
presence of 100 nM dasatinib for 12, 24, and 48 hr.
Cells were collected for RNA harvest and quanti-
tative PCR analysis (E) or were lysed for immunoblot analysis (F). PCR was performed on cDNA with primers specific for ROR1 and GAPDH to determine relative
ROR1mRNA expression levels. Values represent the fold change (normalized to untreated control cells) ± SEM (n = 6) (**p < .01). Immunoblotting was performed
with antibodies specific for ROR1 or b-Actin to determine relative ROR1 protein expression.
See also Figure S3.
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ROR1 and Dasatinib in t(1;19)-ALLboth features were recapitulated in these early passage t(1;19)
xenograft cells (data for one representative cell line are shown
in Figures 2G and 2H).
ROR1 Expression Is Regulated By Pre-BCR Signaling
We next wanted to investigate the functional role for ROR1 in
t(1;19) ALL cells. Because upregulation of ROR1 in both malig-
nant and normal B cell precursors occurs at the pre-BII stage,
we first examined a possible connection with other biological
events known to occur at this same stage of B-lineage matura-
tion. One of the hallmarks of the pre-BII stage is the assembly
and expression of the pre-BCR complex (Figure S3A). As such,
we next examined the possibility of a functional connection
between ROR1 and the pre-BCR. We tested two possibilities:
(1) ROR1 directly interacts with the pre-BCR complex or (2)
pre-BCR signaling may drive ROR1 expression. We began by
examining ROR1 immunoprecipitates from t(1;19) ALL cells but
found no evidence for interaction of ROR1 with Igm or other
constituents of the pre-BCR (Figure S3B). Next, we examined
whether disruption of the pre-BCR would result in decreasedCanROR1 expression. To disrupt pre-BCR signaling, we utilized
siRNA against the immunoglobulin alpha and beta (Iga and Igb)
components of the pre-BCR complex, which have previously
been shown to be necessary for pre-BCR activity (Papavasiliou
et al., 1995; Teh andNeuberger, 1997). As expected, knockdown
of Iga or Igb resulted in significantly impaired t(1;19) ALL cell
viability, which was amplified with simultaneous silencing of
both proteins (Figure 3A). We then analyzed ROR1 expression
following inhibition of the pre-BCR by knockdown of Iga/b. Para-
doxically, knockdown of Iga and Igb did not inhibit ROR1 expres-
sion and instead resulted in significant ROR1 upregulation
(Figure 3B).
The unexpected upregulation of ROR1 after pre-BCR silencing
suggested a functional connection between ROR1 and the
pre-BCR, with ROR1 upregulation after pre-BCR inhibition
potentially representing an intrinsic response mechanism to
perturbation of the pre-BCR pathway. We next examined a
pharmacological approach to inhibition of pre-BCR signaling,
employing the inhibitor dasatinib, which has been previously
described to block mature-BCR signaling (McCaig et al.,cer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier Inc. 659
Figure 4. Dasatinib Inhibits Pre-BCR/SRC/
AKT Signaling and Upregulates ROR1 in
t(1;19) ALL
(A) Schematic of pre-BCR signaling and function
during pre-B development. Adapted from (Herzog
et al., 2009; Monroe, 2006).
(B) RCH-ACV cells were treated with dasatinib
(50 nM) over a time course, and whole-cell
extracts were subjected to immunoblot analysis
for total or phospho-LYN, SYK, Iga, and AKT. In
addition, BTK was immunoprecipitated from the
same cellular lysates, and immunoprecipitates
were immunoblotted for total or phospho-BTK.
(C) RCH-ACV cells were treated with an allosteric
inhibitor of AKT (1 mM) or dasatinib (100 nM) for
24 hr and whole cell extracts were subjected to
immunoblot analysis for ROR1 and b-Actin.
(D and E) RCH-ACV, Kasumi-2, and REH cells
were cultured in graded concentrations of the
kinase inhibitors ponatinib (D) or imatinib (E) for
3 days, at which time cells were subjected to an
MTS assay for measurement of cell viability.
Values represent percentage mean (normalized to
no-drug control wells) ± SEM (n = 6).
(F) Venn-diagram identifies potential phenotype-
mediated targets of dasatinib (CSK, SRC-family
kinases, and EPH receptors). Binding constants
were dasatinib (<10 nM), ponatinib (<25 nM), and
imatinib (<500 nM) (O’Hare et al., 2009; Karaman
et al., 2008).
(G) RCH-ACV cells were treated with ponatinib
(50 nM), PCI-32765 (50 nM), or BMS-599626
(500 nM) over a time course, and whole-cell
extracts were subjected to immunoblot analysis
for total or phospho-AKT.
See also Figure S4.
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ROR1 and Dasatinib in t(1;19)-ALL2011). Similar to siRNA-mediated disruption of the pre-BCR,
inhibition of pre-BCR signaling with dasatinib resulted in
impaired viability and increased apoptosis of the pre-BCR-posi-
tive t(1;19) ALL cell lines RCH-ACV and Kasumi-2, whereas the
pre-BCR-negative t(12;21) ALL cell line REH was insensitive
(Figures 3C and 3D). As with knockdown of Iga/b, dasatinib-
mediated pre-BCR inhibition resulted in further upregulation of
ROR1 mRNA and protein (Figures 3E and 3F; Figure S3C). To
confirm that ROR1 upregulation is not a general response to all
apoptotic stimuli in t(1;19) cells, we treated RCH-ACV cells
with doxorubicin, which induces apoptosis through the p53
pathway and is a therapeutic agent used in the setting of ALL.
We observed robust induction of apoptosis in response to
doxorubicin (Figure S3D); however, ROR1 was not upregulated
and, in fact, exhibited reduced expression (Figure S3E). This
stands in marked contrast to the robust upregulation of ROR1
observed after inhibition of the pre-BCR with dasatinib or
silencing of the pre-BCR with siRNA directed against Iga/b
(Figures 3B and 3F; Figures S3C and S3E).660 Cancer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier Inc.Dasatinib-Inhibited Pre-BCR
Signaling Disrupts AKT in
t(1;19) ALL
The observation that dasatinib recapitu-
lated the phenotype of pre-BCR silencing
(reduction of t(1;19) ALL cell viability andROR1 upregulation) suggested that dasatinib could be a useful
tool to study functional interactions between ROR1 and the
pre-BCR. First, however, we wanted to validate that dasatinib
was operating via inhibition of pre-BCR signaling and also iden-
tify the specific kinase targets of dasatinib in this setting. As
previously described, the pre-BCR is noted for regulation of
both proproliferation and prodifferentiation signaling required
for normal B cell differentiation, and a variety of kinases play
a prominent role in this signaling complex (Figure 4A). We began
by examining putative dasatinib targets that are known to partic-
ipate in this pre-BCR signaling complex. BTK and SRC-family
kinases are established targets of dasatinib (Hantschel et al.,
2007; Karaman et al., 2008) and critical components of the
pre-BCR and mature BCR signaling complexes (Hsueh and
Scheuermann, 2000). Indeed, phosphorylation of BTK and the
SRC-family kinase, LYN, were inhibited after dasatinib exposure.
The additional loss of phosphorylation of pre-BCR complex
components SYK, Iga, and AKT (which are not direct targets
of dasatinib) indicated complete disruption of the pre-BCR
Table 1. ROR1-Associated Proteins Identified by IP-Mass Spectrometry in t(1;19) ALL
Isotype Control ROR1 Antibody
Gene Accession No. Kasumi-2 697 RCH-ACV Kasumi-2 697 RCH-ACV
ROR1 Q01973 0 0 0 30 28 19
TRIM21 P19474 0 0 0 12 0 12
MORC3 Q14149 0 0 0 7 17 18
TBC1D1 Q86TI0 0 0 0 9 1 3
TBC1D4 O60343 0 0 0 9 0 2
ACTB P60709 15 23 26 8 47 26
Lysates from the t(1;19)-positive ALL cell lines (Kasumi-2, 697, and RCH-ACV) were subjected to immunoprecipitation with ROR1-specific antibody or
an isotypematched control. Immunoprecipitates were then analyzed bymass spectrometry (MS). All proteins that were identified at a similar frequency
in isotype controls as ROR1-specific antibody samples were considered to be nonspecific interactions and eliminated. Only proteins that were iden-
tified with ROR1 antibody and not with isotype control were considered as candidate ROR1-interacting proteins. Genes name, UniProt accession
number, and corrected MS/MS spectral counts are shown for each identified protein as well as b-Actin control.
See also Figure S6.
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ROR1 and Dasatinib in t(1;19)-ALLsignaling complex by dasatinib (Figure 4B). In addition, direct
inhibition of AKT with an allosteric inhibitor of AKT (MERCK
AKT1/2; published as drug #17 in Table 2 of Bilodeau et al.,
2008) resulted in ROR1 upregulation, as was also observed
with dasatinib and pre-BCR silencing (Figure 4C). These results
suggested that t(1;19) ALL dasatinib sensitivity occurs as a result
of inhibition of pre-BCR-initiated BTK and/or SRC kinases that
subsequently activate AKT. However, dasatinib has the capacity
to inhibit many other kinases, so we wanted to further validate
this hypothesis. Accordingly, we treated t(1;19) ALL cells with
the SRC kinase inhibitor ponatinib (which lacks activity against
BTK; O’Hare et al., 2009) and observed a phenotype identical
to dasatinib—selective sensitivity of t(1;19) ALL cells and potent
reduction of AKT phosphorylation (Figures 4D and 4G). In
contrast, a third kinase inhibitor, imatinib, exhibited no effect
on t(1;19) ALL cells (Figure 4E). Examination of these three drugs
to understand target genes inhibited by both dasatinib and
ponatinib but not by imatinib revealed that the only candidate
gene targets to explain the dasatinib/ponatinib phenotype are
SRC kinases, EPH receptor kinases, and CSK (Figure 4F). Treat-
ment of these cells with a CSK inhibitor (BMS-599626) or a BTK
inhibitor (PCI-32765) did not recapitulate the dasatinib/ponatinib
phenotype, indicating that dasatinib/ponatinib sensitivity is due
to SRC kinases or EPH receptor kinases (Figure 4G). Examina-
tion of EPH receptor expression revealed that EPHA3 is upregu-
lated in t(1;19) ALL cells (Figure S4A). However, silencing of
EPHA3 did not yield any discernible effect on t(1;19) ALL cell
viability. No other EPH receptors exhibited aberrant expression
in the t(1;19) setting, indicating that EPH receptors are likely
not underlying this dasatinib/ponatinib cell viability response
and suggesting SRC-family kinases as the operationally
important target underlying t(1;19) ALL dasatinib sensitivity
(Figure S4B).
Finally, we closely examined downstream pre-BCR signaling
in the context dasatinib exposure. The pre-BCR is known to
stimulate a prodifferentiation pathway (BTK/BLNK/PLCg2) as
well as a prosurvival/proliferation, antidifferentiation pathway
(PI3K/AKT) (Hashimoto et al., 1999; Herzog et al., 2009). We
observed no effects on phosphorylation of BLNK/PLCg2 after
dasatinib treatment (Figure S4C), which is consistent with our
conclusion that BTK is dispensable for dasatinib-mediatedCant(1;19) ALL cell killing. In contrast, analysis of downstream
AKT substrates revealed activation (reduced phosphorylation)
of FOXO-family transcription factors, upregulation of RAG1
protein, loss of expression of the prosurvival gene BCL6, and
activation (reduced phosphorylation) of proapoptotic BAD—all
of which lead to arrested proliferation and apoptosis (Figure 3D;
Figures S4D–S4F) (Brunet et al., 1999; Datta et al., 1997; Hide-
shima et al., 2010).
ROR1 Drives Signaling Pathways that Are
Compensatory with Pre-BCR Signaling
The increase of ROR1 expression after inhibition of the pre-BCR
signaling complex led us to hypothesize the existence of coun-
terbalancing pools of signaling proteins that function down-
stream of ROR1 or the pre-BCR in a compensatory manner to
influence cell growth and viability. To evaluate this possibility,
we needed to first determine the mechanism by which ROR1
influences downstream signaling pathways. We first examined
the potential tyrosine kinase function of ROR1. However, we
found no evidence of endogenous ROR1 tyrosine phosphoryla-
tion (Figure S5A). Likewise, in vitro kinase activity assays re-
vealed no significant ROR1 kinase activity, a finding consistent
with a recent study showing absence of intrinsic ROR1 kinase
activity (Gentile et al., 2011). Hence, to identify alternativemodal-
ities for activation of signaling cascades by ROR1, we performed
a mass spectrometry-based proteomic screen of proteins asso-
ciating with endogenous ROR1 in t(1;19) ALL. Using three t(1;19)
ALL cell lines (Kasumi-2, 697, and RCH-ACV), we prepared
ROR1 or isotype control immunoprecipitates.We analyzed these
samples with mass spectrometry to identify proteins that specif-
ically and consistently coimmunoprecipitatedwith ROR1 and not
with isotype control. This approach successfully identified four
candidate ROR1 interacting proteins (Table 1; Figure S6). Two
of these proteins (TBC1D1 and TBC1D4) have been reported
to function as RAB GTPase-activating proteins (Park et al.,
2011; Sano et al., 2003), suggesting regulation of small GTPase
signaling as a possible avenue for ROR1 signaling.
Though this work presented a potential mechanism by which
ROR1 can activate downstream signaling pathways, the specific
signaling pathways regulated by ROR1 as well as the manner by
which these pathways interact with the pre-BCR signalingcer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier Inc. 661
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ROR1 and Dasatinib in t(1;19)-ALLcomplex remained unclear. To address these questions, we
examined protein phosphorylation patterns after treatment of
cells with ROR1 siRNA or with dasatinib. We observed three
categories of phosphorylation changes following these treat-
ments: (1) phosphorylation decreased by dasatinib but in-
creased or not changed by ROR1 siRNA, (2) phosphorylation
increased by dasatinib but decreased or not changed by
ROR1 siRNA, or (3) phosphorylation reduced by both dasatinib
and ROR1 siRNA (Figure 5A). Notably, the MAP kinase family
members, MEK and ERK, which are regulated downstream
of small GTPases such as RAS (Mendoza et al., 2011), RAB
(Bhuin and Roy, 2010), and RAC (Wang et al., 2010), exhibited
reduced phosphorylation following ROR1 silencing and in-
creased phosphorylation following dasatinib treatment. In addi-
tion, phosphorylation of AKT at serine 473 was among the
phosphorylation events that were reduced by both dasatinib
and ROR1 siRNA. Independent immunoblotting successfully
validated reduction in phosphorylation of MEK, ERK, and AKT
following ROR1 silencing (Figure 5B). Because AKT was regu-
lated by both dasatinib and ROR1, this represented a potential
signaling node for functional interaction between ROR1 and
the pre-BCR. Consistent with this model, phosphorylation of
AKT at serine 473 is almost completely abrogated after short
time points with dasatinib treatment (1 and 4 hr); however, phos-
phorylation is partially restored at 24 hr once ROR1 expression
has been further induced (Figure 5C). In addition, ROR1 ex-
hibited the capacity to regulate the MEK/ERK cascade, so we
hypothesized that crosstalk between AKT and MEK/ERK
enables ROR1 to regulate AKT and thereby cooperate with the
pre-BCR signaling complex. To test this hypothesis, we simulta-
neously treated cells with dasatinib and a MEK inhibitor,
PD98059. This combination treatment resulted in sustained
reduction of AKT phosphorylation, suggesting the 24 hr partial
AKT recovery may, indeed, be mediated by crosstalk between
MEK/ERK and AKT (Figure 5C). Finally, because STAT3 was
recently described as a regulator of ROR1 expression in CLL
(Li et al., 2010) and we observed increases in STAT3 phosphor-
ylation after dasatinib exposure in t(1;19) ALL cells (Figure 5A;
Figure S5B), we cotreated RCH-ACV cells with dasatinib and
the STAT3 inhibitor S31-201 and we observed prevention of
ROR1 upregulation in response to this drug combination
(Figure S5C).
On the basis of the observed upregulation of ROR1 in
response to pre-BCR inhibition by dasatinib and the compensa-
tory signaling pathway driven by ROR1, we hypothesized that
ROR1 may partially rescue cell survival after inhibition of the
pre-BCR. If this were the case, then targeting of ROR1 in the
context of dasatinib exposure would potentiate dasatinib killing
of t(1;19) cells. To test this hypothesis, we treated t(1;19) ALL
cell lines with nonspecific-, ROR1-, or Iga-targeting siRNA and
subsequently exposed these cells to graded concentrations of
dasatinib. As predicted, cells subjected to ROR1 silencing
were more sensitive to dasatinib compared with cells treated
with nonspecific siRNA, suggesting that ROR1 can function as
a rescue pathway for cell survival in the context of pre-BCR inhi-
bition (Figure 5D). Importantly, knockdown of Iga did not
increase the level of killing when combined with dasatinib, indi-
cating that the ROR1/dasatinib phenotype cannot be achieved
by nonspecific combination of any two cellular insults.662 Cancer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier IncClinical Significance of Dasatinib Sensitivity
in B Cell Malignancies
To determine the clinical significance of dasatinib sensitivity in
t(1;19) ALL, we asked whether primary cells taken directly from
patients with ALL were similarly sensitive to dasatinib exposure.
We tested leukemia cells from ten patients with ALL of varying
disease subsets over graded concentrations of dasatinib. Two
of these ten patient samples were obtained from t(1;19)-positive
patients, and both samples tested were highly sensitive to dasa-
tinib, with IC50 values of approximately 2 and 12 nM, whereas the
eight other ALL samples did not achieve IC50 values even at the
highest tested concentration (1000 nM) (Figure 6A). Importantly,
examination of ROR1 levels in these two t(1;19) patients con-
firmed ROR1 overexpression, similar to levels observed on all
other t(1;19) samples previously tested (Figure 6B).
We next utilized a xenograft model of t(1;19) ALL to examine
dasatinib sensitivity in vivo. The early passage t(1;19) ALL xeno-
graft line ICN12 showed dasatinib sensitivity in vitro at concen-
trations similar to those observed in patient-derived cell lines
and primary samples (Figure 6C). These ICN12, t(1;19)-ALL cells
were then injected into NOD/SCID mice. Following engraftment,
mice were treated with a dose-escalating regimen of dasatinib or
vehicle control, starting with dosages already described for Ph+
ALL (Boulos et al., 2011) and monitored for 60 days. Mice
receiving dasatinib exhibited significantly prolonged survival
compared with vehicle-treated control mice (Figure 6D).
Finally, because t(1;19) ALL does not represent the only
B-lineage malignancy arrested at an intermediate/late stage of
B cell development, we analyzed ROR1 status and dasatinib
sensitivity in additional primary cells from B cell malignancies
arrested at both the intermediate and mature stages of B cell
development. Specifically, we examined primary samples from
patients diagnosed with pre-BCR-positive t(17;19) ALL (as indi-
cated by CD34-negativity and Igm expression; Figures S7A and
S7B), as well as a mature BCR-positive Burkitt’s sample. Both
showed high ROR1 expression levels, similar to those observed
in t(1;19) ALL samples (Figure 6E). As expected, these samples
were also sensitive to dasatinib treatment, with IC50 values
comparable to those of t(1;19) ALL (Figure 6F). These results
support the idea that ROR1 expression and dasatinib sensitivity
are conserved characteristics of B cell malignancies exhibiting
both pre-BCR and mature BCR expression.
DISCUSSION
In agreement with other recent work (Broome et al., 2011; Hude-
cek et al., 2010), we show that ROR1 upregulation in t(1;19) ALL
is a product of B-lineage development arrest at the pre-BII stage
of B cell development and not a result of aberrant regulation by
the E2A-PBX1 transcription factor generated by the 1;19 translo-
cation. Our studies also show that ROR1 is upregulated in
t(17;19) ALL and Burkitt’s leukemia/lymphoma, suggesting that
ROR1 may be expressed in most B cell malignancies arrested
at an intermediate or mature stage of development. This hypoth-
esis is supported by findings showing ROR1 expression in cell
lines and primary samples derived from patients with Mantle
cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)
(Baskar et al., 2008; Fukuda et al., 2008; Hudecek et al., 2010).
Importantly, the expression of ROR1 on cells from the mature.
Figure 5. Inhibition of Pre-BCR or ROR1 Result in Counterbalancing Effects on Signaling
(A) RCH-ACV cells were treated with dasatinib for 24 hr or ROR1 siRNA for 72 hr, and whole-cell extracts were analyzed by phospho-proteomic array. Values on
the graph represent percentage phosphorylation change ± SEM (n = 3) (*p < .05) of a total of 46 phospho-proteins for dasatinib relative to cells in the absence of
any drug and for ROR1 siRNA relative to cells transfected with nonspecific siRNA.
(B) RCH-ACV cells were transfected with ROR1 or nonspecific siRNA for 72 hr, and whole-cell extracts were subjected to immunoblot analysis for ROR1,
phospho-AKT at residue Serine 473, and b-Actin; ROR1, total and phospho-ERK, and b-Actin; and ROR1, total and phospho-MEK, and b-Actin for validation of
ROR1 modulation observed by the phospho-proteomics screen in (A).
(C) RCH-ACV cells were treated with dasatinib (50 nM), PD98059 (50 mM), or both over a time course, and whole-cell extracts were subjected to immunoblot
analysis for total or phospho-AKT at residue Serine 473, ROR1, and b-Actin.
(D) RCH-ACV cells were electroporated in the presence of nonspecific, ROR1-targeting, or Iga-targeting siRNA and then were plated in culture media. After
2 days, graded concentrations of dasatinib were added. Cells were allowed to culture an additional 2 days before they were subjected to an MTS assay for
measurement of cell viability. Values represent percentage mean (normalized to no-drug control wells) ± SEM (n = 5) (*p < .05; **p < .01).
See also Figure S5.
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Figure 6. Clinical Significance of Dasatinib
Sensitivity in Pre-BCR/BCR-Positive Malig-
nancies
(A) Malignant cells from 10 pediatric patients with
ALL exhibiting a variety of chromosomal trans-
locations (2 positive for t(1;19)) were cultured in
graded concentrations of the kinase inhibitor
dasatinib for 3 days, at which time cells were
subjected to an MTS assay for measurement
of cell viability. Values represent percentage
mean (normalized to no-drug control wells) ± SEM
(n = 3).
(B) cDNA derived from primary samples of t(1;19)
patients with ALL 09-809 and 09-812 was
amplified using primers specific for ROR1, E2A-
PBX1, or GAPDH. The t(1;19)-positive (RCH-ACV)
and -negative (REH) cell lines were included for
comparison.
(C) Early passage t(1;19) ALL xenograft cells
(ICN12) were cultured in graded concentrations of
the kinase inhibitor dasatinib for 3 days, at which
time cells were subjected to an MTS assay for
measurement of cell viability. Values represent
percentage mean (normalized to no-drug control
wells) ± SEM (n = 4).
(D) Early passage t(1;19) ALL xenograft cells
(ICN12) were injected intravenously into NOD/
SCID mice. Mice were left untreated for 8 days to
allow engraftment of cells and subdivided into two
groups, one treated with dasatinib and the other
with vehicle control. An initial dose-escalating
round of treatment commenced with 10 mg/kg
dasatinib for 6 days, followed by 50 mg/kg dasa-
tinib for 4 days. Mice were untreated for the
following 24 days, and this was followed by 12
additional days of dasatinib or vehicle treatment.
Mouse survival was monitored over the course of
the treatment.
(E) cDNA derived from t(1;19) ALL, t(17;19) ALL,
Burkitt’s lymphoma, and normal karyotype ALL
primary samples was analyzed for relative ROR1
mRNA expression using quantitative PCR. cDNA
was amplified using primers specific for ROR1 and
GAPDH, and ROR1 levels were normalized to
GAPDH. Values represent mean arbitrary quanti-
tative PCR units ± SEM (n = 3).
(F) t(1;19) ALL, t(17;19) ALL, Burkitt’s lymphoma, and normal karyotype primary samples were cultured in the presence of graded concentrations of dasatinib.
After 3 days, cells were subjected to an MTS assay for measurement of cell viability. Values represent percentage mean, normalized to no-drug control wells.
See also Figure S7.
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ROR1 and Dasatinib in t(1;19)-ALLB-lineage malignancies, CLL, MCL, and Burkitt’s, demonstrates
a deviation from the normal distribution of ROR1 expression
observed in B cell development. Although ROR1 expression is
observed only in the intermediate stage of normal B cell develop-
ment, it is observed in both intermediate and mature B cell
malignancies. This important distinction suggests that retention
or reactivation of ROR1 expression plays a role in maintenance
of cell viability of these mature, malignant B cell clones.
We also show that the cytoplasmic pre-BCR, which is present
in pre-BII progenitor equivalent t(1;19) ALL, is actively stimulating
the PI3K/AKT pathway, and this pathway is inhibited following
pre-BCR inhibition with dasatinib. Interestingly, we find that the
PI3K/AKT component of the pre-BCR pathway can also be
stimulated by ROR1, and inhibition of pre-BCR signaling results
in rapid upregulation of ROR1 and subsequent reactivation of664 Cancer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier IncAKT via ROR1/MEK/ERK signaling. Indeed, cooperation
between AKT and MEK/ERK has been demonstrated during
B-lineage development; likewise, crosstalk between these
signaling pathways is well documented in a variety of settings
(Mendoza et al., 2011). This observation raises interesting ques-
tions about a potential cooperative role for ROR1 and MEK/ERK
signaling in regulating B cell development with the pre-BCR.
Supporting this idea is work that shows MEK/ERK signaling in
pre-B cells can both cooperate with AKT signaling to coordinate
RAG gene expression and drive prosurvival signaling (Novak
et al., 2010; Taguchi et al., 2003). A prosurvival function for
ROR1/MEK/ERK signaling supports our observation of impaired
cell viability following ROR1 silencing in t(1;19) ALL cells and is
consistent with the idea that ROR1 is being upregulated
following pre-BCR/AKT inhibition in an attempt to rescue cell.
Figure 7. Model for ROR1SupportedBCell Development andCross-
talk between ROR1 and the pre-BCR during Therapeutic Modulation
of t(1;19) ALL
(A–D) Schematic of ROR1 and pre-BCR signaling network and function during
normal B cell development and t(1;19)-positive pre-B ALL. Green indicates
active signaling; red indicates inhibited signaling.
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simultaneous ROR1 silencing and pre-BCR inhibition supports
this model.
Taken together, our findings support a model in which normal
B cell progenitors upregulate ROR1 expression in coordination
with assembly and signaling from the pre-BCR complex at the
pre-BII large stage of development. Here, the pre-BCR drives
AKT activation, which inhibits differentiation, drives proliferation
and promotes survival. ROR1-activated MEK/ERK signaling
cooperates with AKT to support convergent prosurvival path-
ways (Figure 7A) (Novak et al., 2010). As normal pre-B cells
transition to immature B cells, the pre-BCR is internalized and
light-chain is recombined, allowing assembly of the mature
BCR. Here, the BLNK/PLCg2 complex inhibits AKT activation
and promotes differentiation. Although loss of AKT activity
allows cell differentiation to proceed, it also represents loss of
an important prosurvival signal. Our model would suggest that
transient expression of ROR1 at this stage of B-lineage differen-
tiation offers an alternative mechanism for prosurvival signaling
through activation of MEK/ERK (Figure 7B) (Taguchi et al.,
2003). In the case of t(1;19) ALL, the t(1;19) lesion generates
the E2A-PBX1 fusion product that contributes to the develop-
mental arrest of B cell progenitors at the pre-BII small stage of
development. Expression and signaling of ROR1 and the pre-
BCR complex are now retained in the malignant progenitor and
provide onco-requisite signaling stimuli critical for the viability
of these malignant cells. Abrogation of ROR1 signaling (with
siRNA) results in inhibition of MEK/ERK activity leading to atten-Canuation of AKT activity and impairment of cell viability (Figure 7C).
Alternatively, inhibition of pre-BCR activity with dasatinib results
in rapid inhibition of the PI3K/AKT pathway and results in loss of
differentiation repression, abrogation of proproliferative signals,
and subsequent impairment of viability. However, inhibition of
the pre-BCR signaling complex also induces feedback activation
of ROR1 expression and further activation of MEK/ERK sig-
naling. In addition to partially supporting prosurvival signaling
throughMEK/ERK, ROR1 upregulation drives partial reactivation
of AKT signaling, resulting in rescue of cell viability (Figure 7D).
As such, modulation of only ROR1 or only the pre-BCR is not
as effective at killing t(1;19) cells as simultaneous antagonism
of both pathways.
The optimal strategy for therapeutic targeting of ROR1
remains unclear. Immunological-based therapies present a
promising therapeutic strategy for specifically targeting ROR1-
positive malignancies. Chimeric antigen receptor (CAR)-modi-
fied T cells targeting B cell lineage-specific surface markers,
such as CD19 and CD20, are actively being investigated in
clinical trials for B cell malignancies (Porter et al., 2011; Till
et al., 2008). Our data suggest that a similar strategy targeting
ROR1 could prove valuable in treating most intermediate and
mature B cell malignancies. In fact, this strategy is already in
development and showing promising results against CLL and
MCL samples (Hudecek et al., 2010). Further study addressing
the potential toxicity of targeting ROR1 surface expression will
be critical for advancing ROR1 targeting as a viable therapeutic
option.
In conclusion, our work provides important evidence of the
biological function of ROR1 in normal B cell development and
B cell malignancy. It expands the pool of patients who could
potentially benefit from ROR1-targeted therapy and has further
suggested a high rate of overlap between the overexpression
of ROR1 and sensitivity to the targeted kinase inhibitor dasatinib.
The addition of t(1;19) and t(17;19) ALL as well as Burkitt’s
leukemia/lymphoma to the growing list of B cell malignancies
that exhibit ROR1 surface expression provides impetus for
further study of ROR1 biology and ROR1-targeted therapies.
Furthermore, although dasatinib does not directly target ROR1,
it does effectively reduce the viability of many ROR1-positive
B cell malignancies due to expression of the pre- or mature-
BCR in these cells. Hence, our work would suggest further
studies that may lead to implementation of dasatinib therapy
for B cell malignancies expressing the pre- or mature-BCR,
which could also be supplemented with ROR1-directed thera-
pies for enhanced efficacy.
EXPERIMENTAL PROCEDURES
Patient Samples
All clinical samples were obtained with informed consent with approval by
the Institutional Review Board of Oregon Health & Science University and
the Children’s Oncology Group. Bone marrow mononuclear cells were sepa-
rated on a Ficoll gradient. Cells were cultured in RPMI-1640 medium with
20% FBS (Atlanta Biologicals), L-glutamine, insulin/transferrin/sodium sele-
nite, penicillin/streptomycin, fungizone (Invitrogen), and 104 M 2-mercaptoe-
thanol (Sigma).
Primary Leukemia Cell Xenograft
Cells (13 106) from a t(1;19) ALL patient bonemarrowwere inoculated via intra
femoral injection into sublethally irradiated (250 cGy) NOD/SCID mice. Whencer Cell 22, 656–667, November 13, 2012 ª2012 Elsevier Inc. 665
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leukemia cells were harvested from bone marrow and spleen. Leukemic
infiltration was confirmed by flow cytometry and cells were suspended in
culture media (MEM-Alpha medium supplemented with 20% FBS, 1% peni-
cillin/streptomycin, and 1% sodium-pyruvate). For in vivo dasatinib treatment,
14 mice were injected with t(1;19)-positive ALL cells and left untreated for
8 days to allow cell engraftment. Mice were then divided into two groups
and treated by oral gavage with dasatinib or vehicle control according to
a dose-escalating protocol, starting with 10 mg/kg daily for 6 days, 50 mg/
kg once daily for 4 days, no treatment for 24 days, and 50 mg/kg twice daily
thereafter. Mouse survival was monitored for 63 days. All mouse experiments
were performed with approval by the Children’s Hospital Los Angeles Institu-
tional Animal Care and Use Committee.
Gene Expression Microarray
A meta-analysis was performed for gene expression microarray analyses of
samples from pediatric patients with ALL and normal B cell progenitor popu-
lations as previously described (Trageser et al., 2009). Data sets were pro-
cessed and normalized using the RMA algorithm, and normalization was
validated on the basis of even expression levels for a set of seven reference
genes (HPRT, COX6B, GUSB, GAPDH, PGK, ACTB, and B2M) among all
tissue samples studied. Gene expression values for the ROR1 probesets
(211057_at and 205805_s_at) and the IGHM probeset (212827_at) were
studied.
siRNA and Kinase Inhibitors
The RAPID assay and other siRNA experiments were performed as previously
described (Tyner et al., 2008, 2009). All siRNAs were from Thermo Fisher
Scientific Dharmacon RNAi Technologies. Dasatinib and PD98059 were
purchased from LC Labs; PCI-32765, BMS-599626, and ponatinib were
purchased from Selleck; doxorubicin was from Sigma; and the allosteric
AKT inhibitor (published as drug #17 in Table 2 of Bilodeau et al., 2008) was
provided by Merck Pharmaceuticals.
Immunoblotting
All immunoblotting was performed using standard protocols. For phospho-
proteomic arrays, Proteome Profiler Human Phospho-Kinase Array assays
(R&D Systems) were used and analyzed according to the manufacturer’s
protocol. Data was analyzed with ImageJ.
Statistical Analyses
For RAPID screens, the mean and standard deviation of all data points on the
plate were computed, and any data points exceeding two standard deviations
of the mean plate value were considered significant. For cell viability, expres-
sion level, and phosphorylation state assays, a Student’s t test was carried out
for each drug dose or siRNA treatment compared with no drug control or
nonspecific siRNA, respectively. Xenograft mouse survival curves were
analyzed using Log-rank (Mantel-Cox) test.
For further experimental details, see Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
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